More Answers Today. More Options Tomorrow.
Combining genetic and biochemical testing to deliver a quick and highly accurate multiomic diagnosis of rare metabolic disorders.
Inherited metabolic disorders (IMDs) are life-long conditions and patients have a wide range of symptoms and needs. They are debilitating, with phenotypic, biochemical and genetic heterogeneity, frequently leading to prolonged diagnostic odysseys.
With a multiomic approach, we can help you and your patients accelerate the critical journey from symptoms to diagnosis by avoiding stepwise testing – saving time, resources, and pivotal years during which IMDs can rapidly progress.
CENTOGENE’s multiomic panel — CentoMetabolic MOx — has been designed to test for a wide range of IMDs — integrating genetic and biochemical testing in one single solution, for the fast and accurate diagnoses.
When genetic variants relevant to a patient are then detected via CentoMetabolic MOx, we automatically complement the analysis with biomarkers and/or enzyme testing if applicable, and include the results in the medical report. CentoMetabolic provides you with the most valuable information for diagnosis decisions, prognosis and therapeutic approaches, laying the roadmap to personalized treatment options.
Why Choose CentoMetabolic MOX?
Multiomic panel integrating genetic and biochemical testing in a single solution, for fast and accurate diagnosis of a wide range of inherited metabolic disorders
Biochemical testing to support variant classification, leading to higher diagnostic yields
Best-in-class medical reports powered by the world’s largest rare disease-centric Bio/Databank from the leader and trusted partner in rare disease diagnostics
Visit Our Online Ordering Portal
CentoPortal® is a user-friendly, online, web-based ordering portal designed to assist you at every step of processing your patients' samples.
Key Features and Performance
|Multiomic Approach||206 genes and over 20 enzymes and biomarkers associated with more than 180 IMDs|
|Improved Interpretation||Extra insights supported by our Bio/Databank, which contains curated unique variant data and omics data from a wide range of ethnicities from more than 120 countries, are used to confirm results and validate pathogenicity of the variants found|
|Advanced and sensitive detection of sequence variants and deletions/duplications||Highly sensitive and specific detection of SNVs, InDels and CNVs |
|Material||CentoCard® (preferred) and blood|
|TAT||15 business days|
SNVs: single nucleotide variants; InDels: small insertions/deletions; CNVs: copy number variations
*CNV detection software has a sensitivity >95.0% for all homozygous/hemizygous deletions, as well as heterozygous deletions/duplications and homozygous/hemizygous duplications spanning at least three consecutive exons
**Variants with low quality and/or unclear zygosity are confirmed by orthogonal methods (i.e., SNVs and InDels by Sanger sequencing; CNVs by Multiplex ligation-dependent probe amplification, MPLA; quantitative polymerase chain reaction, qPCR; or chromosomal microarray, CMA)
Who Should Consider CentoMetabolic MOx?
Physicians providing diagnoses and treatments for patients matching any of the following criteria:
- Suspected metabolic disorder
- Overlapping symptoms and floppy babies
- Infants with lethargy, abdominal pain, vomiting, jaundice, metabolic acidosis
- Abnormal newborn screening results
- Developmental delay
- Infants admitted to a neonatal intensive care unit (NICU), especially due to epilepsy of unclear origin and disturbed consciousness
- Symptoms related to neurological conditions of unknown etiology
What Genes and Disorders Are Targeted?
CentoMetabolic targets close to 200 genes. The content and design of the panel is based on our continuously enhanced medical expertise and knowledge of rare metabolic disorders, including the latest medical and in-house findings.
The table below shows the distribution of genes and targeted metabolic disorders based on 18 different disease categories:
Types of metabolic disorders covered
|Congenital disorders of glycosylation and other disorders of protein modification||2|
|Defects in cholesterol and lipoprotein metabolism||2|
|Defects in hormone biogenesis or function||7|
|Disorder of phosphate, calcium and vitamin D metabolism||3|
|Disorders in the metabolism of purines, pyrimidines and nucleotides||6|
|Disorders in the metabolism of trace elements and metals||6|
|Disorders in the metabolism of vitamins and (non-protein) cofactors||10|
|Disorders of amino acid and peptide metabolism||33|
|Disorders of carbohydrate metabolism||35|
|Disorders of energy metabolism||6|
|Disorders of fatty acid and ketone body metabolism||3|
|Disorders of lipid and lipoprotein metabolism||8|
|Disorders of neurotransmitter metabolism||1|
|Disorders of porphyrin and heme metabolism||8|
|Disorders of the metabolism of sterols||16|
|Porphyria and bilirubinemia||1|
*Due to overlapping phenotypes, particular genes are listed in more than one category as they are associated with more than one disorder
Going Beyond Genetics – What Biomarkers and Enzymatic assays are included?
CentoMetabolic MOx panel includes biomarkers and enzymatic assays for over 20 metabolic disorders. Biomarkers serve as measurable indicators of pathological processes. They are typically directly linked to genetic variants in specific genes and can predict, diagnose, monitor, and assess the severity of a disease. Measuring the cellular activity of an enzyme can also be used as a tool for the diagnosis and monitoring of a disease, as well as treatment efficacy.
Our multiomic- and big data-based approaches allow us to continuously discover new highly specific biomarkers and develop new enzymatic assays. Any new biomarker and biochemical assay clinicaly relevant for metabolic disorders will be included in this panel, and represents an opportunity to advance our understanding of metabolic disorders well as develop better tailored therapies for patients.
CentoMetabolic MOx – Product Sheet
More answers today. More options tomorrow.
Generation of iPSCs for Rare Diseases
Induced pluripotent stem cells (iPSCs) represent excellent in vitro models to study rare diseases and perform high-throughput drug screening. CENTOGENE has established iPSC technology for rare […]
Moving Towards New Therapies for Fabry Disease
Fabry disease is a multi-system lysosomal storage disorder. As it is caused by an enzyme deficiency, enzyme replacement therapy is the standard treatment option. To overcome some of the issues with […]
Diagnostic Utility of Biomarkers
Classification of genomic variants in a disease context is a highly formalized process, which benefits from diverse types of information. At CENTOGENE, this routinely involves the quantification of […]
Enzymes and Biomarkers Included in MOx Products
Enzyme assays and biomarkers included in CentoMetabolic MOx products and corresponding diseases
Oligosaccharidoses and Sphingolipidoses
- Fabry disease
- Schindler/Kanzaki disease
- Gaucher disease
- Tay-Sachs disease
- Sandhoff disease
Neuronal Ceroid Lipofuscinosis
- Jansky-Bielschowsky disease
- Hurler syndrome (MPS I)
- Hunter syndrome (MPS II)
- Sanfilippo syndrome B (MPS III B)
- Morquio syndrome A (MPS IV A)
- Morquio syndrome B (MPS IV B)
- Maroteaux-Lamy syndrome (MPS VI)
- Sly syndrome (MPS VII)
- Gaucher disease
- Fabry disease
Lyso-ceramide trihexoside (lyso-Gb3))
- Niemann-Pick disease type A/B/C
- Aromatic L-amino acid decarboxylase (AADC) deficiency
*A method using Lyso-Gb1 is covered by US Patent No.10,859,580, other pending US applications, and pending applications and patents in other jurisdictions
Our MOx services for improved diagnosis of rare, metabolic and neurodegenerative diseases
A Race Against the Clock – Diagnosing Genetic Conditions in Newborns and Children
Up to one third of all babies and children admitted to the intensive care unit (ICU) have a genetic disease. For many of them early identification can make a difference for their immediate and later […]
Get in Touch With Our Customer Support
Our consultation service is available in several languages.
+49 (0) 381 80 113 - 416
Mon. – Fri. 7 a.m. – 8 p.m. CEST
Sat. 8 a.m. – 12 p.m. CEST